The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries

Background: Until more data are available to shed light on the thyroid disorders related to immune checkpoint inhibitors (ICPi) implemented for the treatment of hematological malignancies, the decision-making is guided by pertinent data derived mostly from solid tumors. Methods: The present review p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria V. Deligiorgi, Sofia Sagredou, Lampros Vakkas, Dimitrios T. Trafalis
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	anti-CTLA-4 monoclonal antibodies anti-PD-1 monoclonal antibodies anti-PD-L1 monoclonal antibodies immune checkpoint inhibitors immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/70cb9f4ce25546f3b5df474d00649bc9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:70cb9f4ce25546f3b5df474d00649bc9
record_format	dspace
spelling	oai:doaj.org-article:70cb9f4ce25546f3b5df474d00649bc92021-11-11T15:26:56ZThe Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries10.3390/cancers132152772072-6694https://doaj.org/article/70cb9f4ce25546f3b5df474d00649bc92021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5277https://doaj.org/toc/2072-6694Background: Until more data are available to shed light on the thyroid disorders related to immune checkpoint inhibitors (ICPi) implemented for the treatment of hematological malignancies, the decision-making is guided by pertinent data derived mostly from solid tumors. Methods: The present review provides a comprehensive and updated overview of the thyroid disorders related to ICPi, namely to inhibitors of cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death (PD) 1 (PD-1), and the ligand of the latter (PD-L1). Results: With the increasing recognition of ir thyroid disorders, many outstanding issues have emerged. Ir thyroid disorders are reminiscent of, but not identical to, thyroid autoimmunity. Interclass and intraclass ICPi differences regarding thyroid immunotoxicity await interpretation. The available data concerning the predictive value of thyroid autoantibodies for the development of ir thyroid disorders are inconclusive. Mounting data indicate an association of ir thyroid disorders with ICPi efficacy, but a causative link is still lacking. The path forward is a tailored approach, entailing: (i) the validation of tumor-specific, patient-specific, and ICPi-specific predictive factors; (ii) appropriate patient selection; (iii) the uncoupling of antitumor immunity from immunotoxicity; (iv) a multidisciplinary initiative; and (v) global registry strategies. Conclusions: Untangling and harnessing the interrelationship of immuno-oncology with endocrinology underlying the ir thyroid disorders will yield the optimal patient care.Maria V. DeligiorgiSofia SagredouLampros VakkasDimitrios T. TrafalisMDPI AGarticleanti-CTLA-4 monoclonal antibodiesanti-PD-1 monoclonal antibodiesanti-PD-L1monoclonal antibodiesimmune checkpoint inhibitorsimmune-related adverse eventsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5277, p 5277 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	anti-CTLA-4 monoclonal antibodies anti-PD-1 monoclonal antibodies anti-PD-L1 monoclonal antibodies immune checkpoint inhibitors immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	anti-CTLA-4 monoclonal antibodies anti-PD-1 monoclonal antibodies anti-PD-L1 monoclonal antibodies immune checkpoint inhibitors immune-related adverse events Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maria V. Deligiorgi Sofia Sagredou Lampros Vakkas Dimitrios T. Trafalis The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
description	Background: Until more data are available to shed light on the thyroid disorders related to immune checkpoint inhibitors (ICPi) implemented for the treatment of hematological malignancies, the decision-making is guided by pertinent data derived mostly from solid tumors. Methods: The present review provides a comprehensive and updated overview of the thyroid disorders related to ICPi, namely to inhibitors of cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death (PD) 1 (PD-1), and the ligand of the latter (PD-L1). Results: With the increasing recognition of ir thyroid disorders, many outstanding issues have emerged. Ir thyroid disorders are reminiscent of, but not identical to, thyroid autoimmunity. Interclass and intraclass ICPi differences regarding thyroid immunotoxicity await interpretation. The available data concerning the predictive value of thyroid autoantibodies for the development of ir thyroid disorders are inconclusive. Mounting data indicate an association of ir thyroid disorders with ICPi efficacy, but a causative link is still lacking. The path forward is a tailored approach, entailing: (i) the validation of tumor-specific, patient-specific, and ICPi-specific predictive factors; (ii) appropriate patient selection; (iii) the uncoupling of antitumor immunity from immunotoxicity; (iv) a multidisciplinary initiative; and (v) global registry strategies. Conclusions: Untangling and harnessing the interrelationship of immuno-oncology with endocrinology underlying the ir thyroid disorders will yield the optimal patient care.
format	article
author	Maria V. Deligiorgi Sofia Sagredou Lampros Vakkas Dimitrios T. Trafalis
author_facet	Maria V. Deligiorgi Sofia Sagredou Lampros Vakkas Dimitrios T. Trafalis
author_sort	Maria V. Deligiorgi
title	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
title_short	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
title_full	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
title_fullStr	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
title_full_unstemmed	The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
title_sort	continuum of thyroid disorders related to immune checkpoint inhibitors: still many pending queries
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/70cb9f4ce25546f3b5df474d00649bc9
work_keys_str_mv	AT mariavdeligiorgi thecontinuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries AT sofiasagredou thecontinuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries AT lamprosvakkas thecontinuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries AT dimitriosttrafalis thecontinuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries AT mariavdeligiorgi continuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries AT sofiasagredou continuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries AT lamprosvakkas continuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries AT dimitriosttrafalis continuumofthyroiddisordersrelatedtoimmunecheckpointinhibitorsstillmanypendingqueries
_version_	1718435316289765376

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries

Ejemplares similares